Ertugliflozin
- Generic Name
- Ertugliflozin
- Brand Names
- Segluromet, Steglatro, Steglujan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25ClO7
- CAS Number
- 1210344-57-2
- Unique Ingredient Identifier
- 6C282481IP
- Background
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus.
Ertugliflozin was first approved by the FDA in December 2017. It was also approved by the European Commission in March 2018.
- Indication
Ertugliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus (T2DM). It is also available in combination with either metformin or sitagliptin.
Ertugliflozin is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2019-02-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 36
- Registration Number
- NCT01948986
Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)
- First Posted Date
- 2010-10-19
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT01223339
A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 6
- Registration Number
- NCT01127308
A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT01018823
A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00989079
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.